Last reviewed · How we verify
PCV chemotherapy
PCV is a chemotherapy regimen combining procarbazine, lomustine (CCNU), and vincristine to disrupt cancer cell DNA and microtubule function.
PCV is a chemotherapy regimen combining procarbazine, lomustine (CCNU), and vincristine to disrupt cancer cell DNA and microtubule function. Used for Recurrent or progressive glioblastoma, Anaplastic oligodendroglioma, Low-grade gliomas.
At a glance
| Generic name | PCV chemotherapy |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Chemotherapy regimen (alkylating agents + vinca alkaloid) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PCV is a multi-agent chemotherapy combination where procarbazine and lomustine act as alkylating agents that cross-link DNA and prevent replication, while vincristine is a vinca alkaloid that disrupts microtubule assembly during mitosis. This triple-agent approach targets rapidly dividing cancer cells through complementary mechanisms of cytotoxicity.
Approved indications
- Recurrent or progressive glioblastoma
- Anaplastic oligodendroglioma
- Low-grade gliomas
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
- Anemia
- Alopecia
- Secondary malignancy risk
Key clinical trials
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (PHASE1)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (PHASE3)
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (PHASE3)
- gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas (PHASE3)
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (PHASE3)
- Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients
- Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV chemotherapy CI brief — competitive landscape report
- PCV chemotherapy updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI